Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960893 · ClinicalTrials.gov registry record · Phase 2
Trial in Adult Participants With Spinocerebellar Ataxia (SCA)
A Phase 2 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Genotype Type 1, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 18
- Study locations
NCT02960893 is a Phase 2 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Genotype Type 1 that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 141 participants, below the 450-participant average among 5 other Spinocerebellar Ataxias trials with a reported enrollment target (69% lower). The trial reports 18 study locations across 11 states.
The verdict
NCT02960893, a Phase 2 study of Spinocerebellar Ataxias and Spinocerebellar Ataxia Genotype Type 1, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 18
- Study locations
Study Summary
The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Troriluzole
Study Locations (18)
California
- CNS Trial - Long Beach
- University of California, Los Angeles - Los Angeles
- University of California, San Francisco - San Francisco
Florida
- University of Florida - Gainesville
- University of South Florida - Tampa
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Massachusetts
- Harvard University (Massachusetts General Hospital) - Boston
- Harvard University (Beth Israel Deaconess Medical Center) - Boston
New York
- Columbia University - New York
- University of Rochester Medical Center - Rochester
Texas
- University of Texas Southwestern - Dallas
- Houston Methodist Research Center - Houston
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Colorado
- University of Colorado Denver - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2016-12-15 |
| Est. Completion | 2024-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960893
The ClinicalTrials.gov registry entry for NCT02960893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 450-participant average among 5 other Spinocerebellar Ataxias trials with a reported enrollment target (69% lower). The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Spinocerebellar Ataxias appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02960893 reports 18 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02960893 about?
NCT02960893 is a clinical study titled "Trial in Adult Participants With Spinocerebellar Ataxia (SCA)". The primary purpose of this study was to compare the efficacy of BHV-4157 (Troriluzole) 140 milligrams (mg) once daily versus placebo after 8 weeks of treatment in participants with spinocerebellar ataxia (SCA).
What is the current status of trial NCT02960893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2016-12-15. Estimated completion is 2024-09-20.
What conditions does trial NCT02960893 study?
This clinical trial studies the following conditions: Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3, Spinocerebellar Ataxia Genotype Type 6.
What interventions are being tested in trial NCT02960893?
The interventions under investigation include: Placebo (DRUG), Troriluzole (DRUG).
Who is sponsoring clinical trial NCT02960893?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02960893 being conducted?
This trial has 18 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinocerebellar Ataxias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
RECRUITING
-
Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
ACTIVE NOT RECRUITING
-
Open Pilot Trial of BHV-4157
ACTIVE NOT RECRUITING · Phase 3
-
Troriluzole in Adult Participants With Spinocerebellar Ataxia
ACTIVE NOT RECRUITING · Phase 3
-
Aerobic Exercise, Balance Training, and Ataxia
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.